Should we use this for Burkitt lymphoma?
It is normally reviewed for Philadelphia negative ALL...involving the T-cell...
"Blinatumomab received the FDA's Breakthrough Therapy designation earlier this year (OT 8/10/14 issue),
which was enacted as part of the FDA's 2012 Safety and Innovation Act
to expedite the development and review time of a potential new drug for
serious or life-threatening disease where early clinical evidence
suggests the drug may demonstrate substantial improvement compared with
existing therapies." From Oncology Times
No comments:
Post a Comment